01—Abstract
Summary
Summary of the 8-K filed December 13, 2024. Cited figures are marked; the original filing is the authoritative source.
On December 13, 2024, Charles River Laboratories International, Inc. ("Charles River") entered into its Tenth Amended and Restated Credit Agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent.
The amendment extends the maturity date for the facilities, reduces aggregate revolving commitments from $3 billion to $2 billiona, adds Charles River Laboratories, Inc. ("CRL"), a direct subsidiary, as a borrower, and makes other changes to covenants and terms. The revolving facility provides up to approximately $2 billion, is available in U.S. dollars to Charles River and CRL and in euros and sterling to certain subsidiaries in the United Kingdom, the Netherlands and Luxembourg, and matures on December 13, 2029, with no scheduled payments required before that date. Borrowings bear interest at base rate, Term SOFR, EURIBOR or daily simple RFR rates, plus a margin based on Charles River's leverage ratio.
Obligations are guaranteed by CRL and secured by substantially all assets of Charles River, CRL and future material domestic subsidiaries, including a pledge of 100%b of the capital stock of CRL and future material domestic subsidiaries and 65% of the capital stock of certain first-tier material foreign subsidiaries. The agreement requires compliance with an interest coverage ratio test and a leverage ratio test and includes negative covenants limiting additional indebtedness, liens, investments, mergers and acquisitions, asset sales, subsidiary distribution restrictions, affiliate transactions and changes to the business. The full agreement is filed as Exhibit 10.1 and incorporated by reference.
02—Key points
Key Highlights
- Tenth Amended and Restated Credit Agreement dated December 13, 2024, filed under Item 2.03 as a direct financial obligation.
- Aggregate revolving commitments reduced from $3 billion to $2 billion.
- Revolving facility maturity extended to December 13, 2029, with no scheduled payments before maturity.
- CRL (Charles River Laboratories, Inc.), a direct subsidiary, added as a borrower and guarantor of Charles River's obligations.
- Obligations secured by substantially all assets of Charles River, CRL and future material domestic subsidiaries, including pledges of 100% of domestic and 65% of certain foreign subsidiary capital stock.
- Multicurrency availability in U.S. dollars, euros and sterling, with borrowers in the UK, Netherlands and Luxembourg.
- Financial covenants include an interest coverage ratio test and a leverage ratio test, alongside broad negative covenants.
03—Questions
Frequently Asked Questions
What changed in Charles River's credit facility?
The Tenth Amended and Restated Credit Agreement extends the maturity date, reduces aggregate revolving commitments from $3 billion to $2 billion, adds CRL as a borrower, and makes other covenant and term amendments.
When does the revolving facility mature and are there scheduled payments?
The revolving facility matures on December 13, 2029, and requires no scheduled payment before that date.
What currencies and borrowers are covered by the revolving facility?
The facility is available in U.S. dollars to Charles River and CRL, and in euros and sterling to Charles River and certain subsidiaries based in the United Kingdom, the Netherlands and Luxembourg.
How is the credit facility secured and guaranteed?
Subject to customary exceptions, Charles River's obligations are guaranteed by CRL and secured by substantially all assets of Charles River, CRL and future material domestic subsidiaries, including a pledge of 100% of the capital stock of CRL and future material domestic subsidiaries and 65% of the capital stock of certain first-tier material foreign subsidiaries.
What restrictions does the agreement place on the company?
The agreement requires compliance with interest coverage and leverage ratio tests and includes negative covenants that, subject to significant exceptions, limit additional indebtedness or guarantees, liens, investments and loans, mergers, acquisitions and asset sales, subsidiary distribution restrictions, affiliate transactions and changes to the business.
04—Continue